Boross P - Search Results

1

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH. Boross P, et al. Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31. Haematologica. 2011. PMID: 21880632 Free PMC article.

2

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH. de Haij S, et al. Among authors: boross p. Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30. Cancer Res. 2010. PMID: 20354182

3

Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.

Boross P, Jansen JH, Pastula A, van der Poel CE, Leusen JH. Boross P, et al. Immunol Lett. 2012 Mar 30;143(1):44-52. doi: 10.1016/j.imlet.2012.01.004. Epub 2012 Jan 23. Immunol Lett. 2012. PMID: 22285696

4

Mechanisms of action of CD20 antibodies.

Boross P, Leusen JH. Boross P, et al. Am J Cancer Res. 2012;2(6):676-90. Epub 2012 Nov 20. Am J Cancer Res. 2012. PMID: 23226614 Free PMC article.

5

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH. Boross P, et al. EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929. EMBO Mol Med. 2013. PMID: 23918228 Free PMC article.

6

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG.

van der Poel CE, Karssemeijer RA, Boross P, van der Linden JA, Blokland M, van de Winkel JG, Leusen JH. van der Poel CE, et al. Among authors: boross p. Blood. 2010 Dec 9;116(24):5327-33. doi: 10.1182/blood-2010-04-280214. Epub 2010 Aug 30. Blood. 2010. PMID: 20805361 Free article.

7

Boosting antibody therapy with complement.

Boross P, Leusen JH. Boross P, et al. Blood. 2012 Jun 21;119(25):5945-7. doi: 10.1182/blood-2012-04-420760. Blood. 2012. PMID: 22730521 Free article.

8

Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions.

Stemerding AM, Köhl J, Pandey MK, Kuipers A, Leusen JH, Boross P, Nederend M, Vidarsson G, Weersink AY, van de Winkel JG, van Kessel KP, van Strijp JA. Stemerding AM, et al. Among authors: boross p. J Immunol. 2013 Jul 1;191(1):353-62. doi: 10.4049/jimmunol.1203243. Epub 2013 Jun 5. J Immunol. 2013. PMID: 23740955

9

Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.

Boross P, Jansen JH, van Tetering G, Nederend M, Brandsma A, Meyer S, Torfs E, van den Ham HJ, Meulenbroek L, de Haij S, Leusen JH. Boross P, et al. Immunol Lett. 2014 Aug;160(2):151-7. doi: 10.1016/j.imlet.2014.02.005. Epub 2014 Mar 5. Immunol Lett. 2014. PMID: 24613852

10

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.

Meyer S, Leusen JH, Boross P. Meyer S, et al. Among authors: boross p. MAbs. 2014;6(5):1133-44. doi: 10.4161/mabs.29670. Epub 2014 Oct 30. MAbs. 2014. PMID: 25517299 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters